KR100628209B1 - 헤데라게닌3-O-α-L-람노피라노실(1→2)-[β-D-글루코피라노실(1→4)]-α-L-아라비노피라노사이드 또는 그를 함유하는백두옹 추출물의 고형암 치료제로서의 용도 - Google Patents
헤데라게닌3-O-α-L-람노피라노실(1→2)-[β-D-글루코피라노실(1→4)]-α-L-아라비노피라노사이드 또는 그를 함유하는백두옹 추출물의 고형암 치료제로서의 용도 Download PDFInfo
- Publication number
- KR100628209B1 KR100628209B1 KR1020050090609A KR20050090609A KR100628209B1 KR 100628209 B1 KR100628209 B1 KR 100628209B1 KR 1020050090609 A KR1020050090609 A KR 1020050090609A KR 20050090609 A KR20050090609 A KR 20050090609A KR 100628209 B1 KR100628209 B1 KR 100628209B1
- Authority
- KR
- South Korea
- Prior art keywords
- baekduong
- fraction
- water
- glucopyranosyl
- hederagenin
- Prior art date
Links
- 0 CC(C)(CC1)CC2C3=CCC([C@@](C)(CC4)C(CC5)[C@](C)(CO)[C@]4O*)[C@]5(C)[C@]3(C)CCC12C(O)=O Chemical compound CC(C)(CC1)CC2C3=CCC([C@@](C)(CC4)C(CC5)[C@](C)(CO)[C@]4O*)[C@]5(C)[C@]3(C)CCC12C(O)=O 0.000 description 2
- RNYZJZKPGHQTJR-UHFFFAOYSA-N C=C(C=C1)OC1=O Chemical compound C=C(C=C1)OC1=O RNYZJZKPGHQTJR-UHFFFAOYSA-N 0.000 description 1
- JLUQTCXCAFSSLD-UHFFFAOYSA-N O=C1OC(CC2)(C2(C=C2)OC2=O)C=C1 Chemical compound O=C1OC(CC2)(C2(C=C2)OC2=O)C=C1 JLUQTCXCAFSSLD-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/256—Polyterpene radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
분획 및 물질 | 마우스 수 | 암성장 억제율(%) | |
14 일a) | 15 일 | ||
WT | 5 | 56 | 55 |
SPX1 | 5 | 10 | 12 |
SPX2 | 5 | 25 | 30 |
SPX3 | 5 | 57 | 60 |
SPX4 | 5 | 8 | 10 |
SB365 | 5 | 82 | 79 |
아드리아마이신 | 5 | 60 | 64 |
그룹 | NCI-H23에 대한 암성장 억제율 (%) | ||||
음성 대조군 | 아드리아마이신 (0.5 ㎎/㎏) | SB365 (1.6 ㎎/㎏) | SB365 (3.2 ㎎/㎏) | SB365 (6.4 ㎎/㎏) | |
16 일a) | - | 61.5 | 40.1 | 52.3 | 82.1 |
Claims (5)
- 유효성분으로서, 헤데라게닌 3-O-α-L-람노피라노실(1→2)-[β-D-글루코피라노실(1→4)]-α-L-아라비노피라노사이드를 함유하고,백두옹(Pulsatillae radix)을 에탄올 수용액으로 추출한 후 아세톤을 가하여 침전시키는 단계를 포함하는 방법에 의해 얻어지는, 백두옹의 수용성 분획을 포함하되,상기 백두옹의 수용성 분획을 1 일 용량 200∼300 ㎎/㎏ 체중으로 투여하는 고형암 치료제.
- 삭제
- 제1항에 있어서, 백두옹의 수용성 분획이 추가로 세파덱스(Sephadex) LH20 칼럼을 통해 통과시켜 얻어지는, Rf가 0.48∼0.50(전개용매; 부탄올:아세트산:물=4:1:1)이고, 황산 분무 후 가열 시 적색을 나타낸 후 청색을 나타내는 분획인 치료제.
- 제3항에 있어서, 백두옹의 수용성 분획을 1 일 용량 20∼40 ㎎/㎏ 체중으로 투여하는 치료제.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 생리식염수, 링거액 및 영양제로 구성된 그룹으로터 선택되는 수액에 용해시켜 투여하는 치료제.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050090609A KR100628209B1 (ko) | 2005-09-28 | 2005-09-28 | 헤데라게닌3-O-α-L-람노피라노실(1→2)-[β-D-글루코피라노실(1→4)]-α-L-아라비노피라노사이드 또는 그를 함유하는백두옹 추출물의 고형암 치료제로서의 용도 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050090609A KR100628209B1 (ko) | 2005-09-28 | 2005-09-28 | 헤데라게닌3-O-α-L-람노피라노실(1→2)-[β-D-글루코피라노실(1→4)]-α-L-아라비노피라노사이드 또는 그를 함유하는백두옹 추출물의 고형암 치료제로서의 용도 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020020043016A Division KR100568607B1 (ko) | 2002-07-22 | 2002-07-22 | 헤데라게닌3-O-α-L-람노피라노실(1→2)-[β-D-글루코피라노실(1→4)]-α-L-아라비노피라노사이드 또는 그를 함유하는백두옹 추출물의 고형암 치료제로서의 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050105942A KR20050105942A (ko) | 2005-11-08 |
KR100628209B1 true KR100628209B1 (ko) | 2006-09-27 |
Family
ID=37283036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050090609A KR100628209B1 (ko) | 2005-09-28 | 2005-09-28 | 헤데라게닌3-O-α-L-람노피라노실(1→2)-[β-D-글루코피라노실(1→4)]-α-L-아라비노피라노사이드 또는 그를 함유하는백두옹 추출물의 고형암 치료제로서의 용도 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100628209B1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102178688B (zh) * | 2011-04-07 | 2012-11-21 | 江西本草天工科技有限责任公司 | 一种常春藤皂苷类成分的制备方法及其抗肿瘤的用途 |
KR101141810B1 (ko) * | 2011-07-28 | 2012-05-07 | 연세대학교 산학협력단 | 신규 항암제 풀사틸라 사포닌 d 및 이의 중간체 합성 |
-
2005
- 2005-09-28 KR KR1020050090609A patent/KR100628209B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20050105942A (ko) | 2005-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7682638B2 (en) | Use of hederagenin 3-O-α-L-rhamnopyranosyl(1-2)-[β-D-glucopyranosyl(1-4)]-α-L-arabinopyranoside or an extract from pulsatillae radix containing the same as a therapeutic agent for solid tumors | |
Rashan et al. | Characterization of the anticancer properties of monoglycosidic cardenolides isolated from Nerium oleander and Streptocaulon tomentosum | |
KR100941662B1 (ko) | 글루타티온 증강용 조성물 | |
Bellila et al. | Cytotoxic activity of withanolides isolated from Tunisian Datura metel L. | |
CN101772511A (zh) | 通过影响粘连蛋白质表达阻止癌细胞的转移和新化合物及其应用 | |
Georgieva et al. | Antiproliferative and antitumour activity of saponins from Astragalus glycyphyllos on myeloid Graffi tumour | |
KR20220061070A (ko) | 오리나무 추출물로부터 분리된 화합물 1을 함유하는 골격근 근육관련 질환의 예방 및 치료용 조성물 | |
KR100628209B1 (ko) | 헤데라게닌3-O-α-L-람노피라노실(1→2)-[β-D-글루코피라노실(1→4)]-α-L-아라비노피라노사이드 또는 그를 함유하는백두옹 추출물의 고형암 치료제로서의 용도 | |
CN101624387B (zh) | 一种异土木香内酯的提纯制备方法和其在制备抗肿瘤药物中的应用 | |
EP4349845A1 (en) | Novel isoflavone compound | |
KR102556464B1 (ko) | 월견초 추출물을 유효성분으로 함유하는 종양증식 억제용 조성물 | |
KR20070036431A (ko) | 항암 활성을 갖는 봄맞이 추출물 및 이로부터 분리된 트리테르펜 사포닌 화합물 | |
Lee et al. | Inhibitory effect of berberine from Coptidis rhizoma on melanin synthesis of murine malignant melanoma | |
KR101186264B1 (ko) | 산자나무 추출물 또는 이로부터 분리된 화합물을 포함하는 il-6으로 매개되는 질환 또는 라이노바이러스 감염성 질환의 예방 또는 치료용 조성물 | |
WO2022235050A1 (ko) | 지유 추출물을 유효성분으로 함유하는 종양증식 억제용 조성물 | |
CN1962684B (zh) | 一类三萜皂苷化合物、其制备方法及用途 | |
KR102268932B1 (ko) | 화학식 1로 표시되는 화합물을 포함하는 암의 예방 또는 치료용 조성물 | |
CN111875662B (zh) | 一种美花铁线莲茎化学提取物的提取方法和应用 | |
US20240254156A1 (en) | Novel isoflavone compound | |
CN117402196A (zh) | 抗肿瘤活性化合物及其制法和应用 | |
KR20120090118A (ko) | 자귀나무 추출물을 포함하는 항암 또는 항암 보조용 조성물 | |
KR20150098599A (ko) | 만병초 추출물 또는 이로부터 분리된 메가스티그메인 배당체를 함유하는 패혈증의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121010 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20131219 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140919 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150911 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160902 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20171017 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20181017 Year of fee payment: 13 |